Pharmacokinetic/Pharmacodynamic Study of Ilaprazole to Evaluate the Effect of CYP Genetic Polymorphism

Effects of genetic polymorphisms on the pharmacokinetics or pharmacodynamics were measured in healthy Korean volunteers

Inclusion criteria

• healthy adult volunteer between 20 and 45 years of age and within 20% of ideal body weight
• No congenital or acquired chronic disease
• appropriate for the study judging from examinations (hematology, chemistry, urinalysis and so on), vital sign and ECG results
• sign the informed consent form prior to study participation

Exclusion criteria

• received any metabolizing enzymes or transporters inducing or inhibiting drugs like barbiturates within 1 month prior to the date of first drug administration
• history of hypersensitivity against drugs or clinically significant allergic diseases
• abnormal laboratory results
• positive result for helicobacter pylori infection from the Urea Breath Test
• alcohol or drug abuser
• pregnant or lactating
• donated whole blood within 60days prior to the study